Roughly 30 million American adults have obstructive sleep apnea, and an estimated 80 percent of them are undiagnosed. The consequences are not limited to daytime fatigue — untreated OSA increases the risk of hypertension, atrial fibrillation, heart failure, and stroke. This is the practical map: what collapses, how it is measured, and how CPAP actually changes the disease.
Obstructive sleep apnea is a mechanical disorder of the upper airway. The airway is held open during wakefulness by the pharyngeal dilator muscles — particularly the genioglossus (which pulls the tongue forward) and the palatal muscles. During sleep, muscle tone naturally decreases. In most people this does not matter. In someone with a narrow pharyngeal airway, a large tongue, excess soft tissue, or a recessed jaw, the airway can collapse under the negative pressure of inspiration — closing the throat like a one-way valve.
Once the airway closes, three things happen in sequence. First, oxygen saturation drops as the lungs receive no fresh air. Second, respiratory effort continues — the chest and diaphragm keep working against a closed airway, generating large negative intrathoracic pressure. Third, the brain detects the problem and briefly arouses the patient out of sleep — usually for just a few seconds, often without any conscious memory. Muscle tone returns, the airway opens, airflow resumes, and the cycle begins again.
Each cycle produces two distinct injuries. The intermittent hypoxia from each desaturation triggers a burst of sympathetic activation — the "fight or flight" response — which raises blood pressure, heart rate, and inflammatory markers. And the arousals fragment sleep architecture, eliminating the deep slow-wave and REM stages that are essential for restoration, memory consolidation, and hormonal regulation. Over hours and years, these repeated events produce the cardiovascular, metabolic, and cognitive consequences of OSA.
What closes the airway varies between patients. Common contributing factors include excess soft tissue in the neck, a large tongue base, retrognathia (recessed lower jaw), enlarged tonsils (particularly in children), nasal obstruction, and hormonal factors — which is why hypothyroidism and acromegaly are recognized risk conditions. Men are roughly 2 to 3 times more likely than women to have OSA before menopause — after menopause, the gap narrows significantly.
Pharyngeal dilators relax during sleep. In a susceptible airway, this narrows the lumen significantly.
Negative inspiratory pressure closes the pharynx. Airflow stops but breathing effort continues — producing the "paradoxical" effort seen on the thoracic effort channel.
SpO₂ falls, the brain detects the fall, and a microarousal briefly restores muscle tone. Sleep architecture is fragmented.
Each arousal triggers a burst of catecholamines. Repeated hundreds of times per night, this drives hypertension, insulin resistance, and cardiovascular damage.
The AHI is the number of apnea and hypopnea events per hour of sleep. An apnea is a complete cessation of airflow for at least 10 seconds; a hypopnea is a partial reduction with associated oxygen desaturation or arousal. The AHI is the primary endpoint on any sleep study.
Fewer than five events per hour. Not diagnostic of OSA — though a patient with symptoms and AHI between 3 and 5 may still have clinically significant upper airway resistance syndrome.
Five to fifteen events per hour. Treatment depends on symptoms and comorbidities. Oral appliances, weight loss, positional therapy, and lifestyle modification may suffice. CPAP for symptomatic patients.
Fifteen to thirty events per hour. CPAP is the standard of care. Cardiovascular risk increases substantially. Oral appliance is an alternative for CPAP-intolerant patients with careful follow-up.
More than thirty events per hour. CPAP is strongly indicated — the cardiovascular, metabolic, and mortality consequences of untreated severe OSA are well documented. Hypoglossal nerve stimulation is a viable option for CPAP-intolerant patients in this group.
OSA is underdiagnosed because its cardinal symptoms occur during sleep, when the patient is not aware of them. It is often a bed partner, not the patient, who first raises the concern.
The most common reported symptom. Not all snoring is OSA, but nearly all OSA involves snoring — and snoring that is loud enough to be heard through a closed door is more suspicious. The snoring pattern often alternates with silence (the apnea) and a loud gasp or snort (the arousal).
Bed partners may report pauses in breathing followed by gasping or choking. This is the single most specific symptom — when a bed partner describes this pattern, the pretest probability of OSA is high.
Excessive daytime sleepiness — measured formally with the Epworth Sleepiness Scale — is a core symptom. Patients may fall asleep while driving, watching TV, or in meetings. Do not dismiss as "just tired."
Morning headaches reflect nocturnal hypercapnia and are common in OSA. Dry mouth and sore throat on waking reflect mouth breathing during the night. Neither symptom alone is diagnostic — but together with snoring they raise suspicion.
CPAP remains the first-line treatment for moderate to severe OSA. Adherence — not acquisition — is the central challenge: as many as 40 to 50 percent of patients abandon CPAP within the first year. Modern devices with humidification, auto-titration, and mask variety substantially improve tolerance.
Continuous positive airway pressure delivers a constant stream of air that acts as a pneumatic splint, holding the pharynx open. When used consistently, it nearly eliminates apneas and hypopneas, restores sleep architecture, and reduces daytime sleepiness.
Auto-titrating PAP (APAP) adjusts pressure breath-by-breath within a preset range — often more comfortable and increasingly the default. BiPAP is reserved for patients who require high pressures or have central apnea or comorbid hypoventilation.
A custom-fitted oral appliance that holds the lower jaw and tongue forward during sleep, enlarging the pharyngeal airway. Best for mild to moderate OSA and for patients who cannot tolerate CPAP. Fitted by a dentist with sleep medicine training.
Less effective than CPAP for severe OSA — a follow-up sleep study is required to confirm adequate control. Common side effects include jaw discomfort, dental changes, and dry mouth.
An implanted device that stimulates the hypoglossal nerve during inspiration, protracting the tongue and opening the airway. Approved for moderate to severe OSA in CPAP-intolerant patients who meet specific criteria.
Not appropriate for everyone — requires a drug-induced sleep endoscopy to confirm the airway collapse pattern is favorable. Effective in about two-thirds of appropriately selected patients. Implanted under general anesthesia, controlled by a remote.
Weight loss is the most effective long-term intervention in overweight patients with OSA — a 10 percent weight reduction can reduce AHI by up to 26 percent. GLP-1 receptor agonists such as tirzepatide and semaglutide have shown substantial AHI reduction in recent trials.
Positional therapy for supine-predominant OSA (avoiding back-sleeping with a positional device or vibrating trainer) helps selected patients. Alcohol and sedatives should be avoided in the evening — they worsen airway collapsibility. Nasal decongestion, allergy control, and smoking cessation all help.
Options include uvulopalatopharyngoplasty (UPPP), maxillomandibular advancement (MMA), tonsillectomy (particularly in children), and nasal surgery. Success rates vary widely, and surgery is generally reserved for patients who cannot tolerate or do not respond to CPAP and other less invasive options.
Children with OSA frequently have adenotonsillar hypertrophy — adenotonsillectomy is the first-line treatment in that population and often curative. Not the same disease as adult OSA.
The repetitive cycles of intermittent hypoxia and sympathetic activation that define OSA do not stay contained to the airway. Over years, they produce measurable cardiovascular and metabolic damage.
The strongest association. OSA is present in up to 40 percent of patients with hypertension, and is a common cause of resistant hypertension — high blood pressure that does not respond to three or more medications. Treating OSA with CPAP reduces blood pressure modestly.
Untreated OSA increases the risk and recurrence of atrial fibrillation. Patients with AFib who undergo cardioversion or ablation have higher recurrence rates if their OSA is untreated. Screening for OSA is now standard practice in AFib care.
OSA is common in both HFrEF and HFpEF. The nocturnal negative intrathoracic pressure increases left ventricular afterload, and sympathetic activation promotes adverse remodeling. Treating OSA can improve functional status and reduce hospitalizations.
OSA is an independent risk factor for ischemic stroke — mediated by hypertension, atrial fibrillation, and inflammatory pathways. Prevalence of OSA after stroke is high, and treatment may reduce recurrence risk.
Intermittent hypoxia independently promotes insulin resistance and worsens glycemic control in type 2 diabetes. The interaction between OSA and metabolic disease is bidirectional — obesity increases OSA risk, and OSA worsens metabolic dysfunction. A reference on what is Metformin used for illustrates the parallel pathway in diabetes management.
Chronic intermittent hypoxia and sleep fragmentation are associated with reduced attention, memory, and executive function. Long-term, untreated severe OSA is associated with an increased risk of cognitive decline — though causality remains under investigation.
Most commercial insurance and Medicare cover sleep studies and CPAP therapy when ordered by a physician with appropriate documentation. However, the pathway usually requires: a referral to a sleep specialist, a diagnostic study (in-lab or home), a PAP titration study, and a documented trial of CPAP therapy with adherence data. Home sleep apnea testing has simplified the diagnostic phase substantially for patients with high pretest probability of moderate to severe OSA — it is now often the preferred first test.
CPAP devices themselves have become more affordable. Older fixed-pressure machines are increasingly available at reduced cost, and manufacturers offer monthly rental or purchase plans through DME suppliers. In 2024, some manufacturers introduced fixed-price direct-to-consumer programs that bypass traditional DME billing. Masks and supplies are the most common ongoing cost — and Medicare and most insurers cover replacement on a defined schedule.
For patients on multiple chronic medications — which is common in OSA, given the frequent coexistence of hypertension, diabetes, and dyslipidemia — pharmacy-level pricing continues to matter. The same medication can cost meaningfully more at one licensed pharmacy than another. If you would like to see what compliant online ordering looks like for a commonly prescribed chronic medication, this guide on Metformin online prescription walks through the process: prescription first, licensed seller second, small first order third.
Before filling from any seller — online or local — verify them. A working VIPPS seal that resolves to a live NABP record, a real U.S. street address, and a prescription requirement that cannot be waived. Sleep apnea is a chronic condition with lifelong consequences; the pharmacies you use should be ones you can hold accountable.
Many of the medications that patients with sleep apnea also take — for hypertension, diabetes, or dyslipidemia — are chronic, generics, and priced differently from one licensed pharmacy to another. A short comparison across sellers is a useful habit for any patient managing multiple conditions. The same approach that resources like Metformin price comparison use applies to every generic on the list.
Open the price comparison